|
|
Blood, 4 June 2009, Vol. 113, No. 23, pp. 5927-5937.
Prepublished online as a Blood First Edition Paper on February 3, 2009; DOI 10.1182/blood-2008-07-171389.
 Previous Article | Table of Contents | Next Article 
LYMPHOID NEOPLASIA
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid–based proteasome inhibitors
Encouse B. Golden1,
Philip Y. Lam2,
Adel Kardosh3,
Kevin J. Gaffney4,
Enrique Cadenas2,
Stan G. Louie5,
Nicos A. Petasis4,
Thomas C. Chen1,6, and
Axel H. Schönthal3
1 Department of Pathology, University of Southern California (USC) Keck School of Medicine (KSOM), Los Angeles;
2 Department of Molecular Pharmacology and Toxicology, USC School of Pharmacy (SoP), Los Angeles;
3 Department of Molecular Microbiology and Immunology, USC KSOM, Los Angeles;
4 Department of Chemistry, USC College of Letters, Arts and Sciences, Los Angeles;
5 Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, USC SoP, Los Angeles; and
6 Department of Neurosurgery, USC KSOM, Los Angeles
The anticancer potency of green tea and its individual components is being intensely investigated, and some cancer patients already self-medicate with this "miracle herb" in hopes of augmenting the anticancer outcome of their chemotherapy. Bortezomib (BZM) is a proteasome inhibitor in clinical use for multiple myeloma. Here, we investigated whether the combination of these compounds would yield increased antitumor efficacy in multiple myeloma and glioblastoma cell lines in vitro and in vivo. Unexpectedly, we discovered that various green tea constituents, in particular (-)-epigallocatechin gallate (EGCG) and other polyphenols with 1,2-benzenediol moieties, effectively prevented tumor cell death induced by BZM in vitro and in vivo. This pronounced antagonistic function of EGCG was evident only with boronic acid–based proteasome inhibitors (BZM, MG-262, PS-IX), but not with several non–boronic acid proteasome inhibitors (MG-132, PS-I, nelfinavir). EGCG directly reacted with BZM and blocked its proteasome inhibitory function; as a consequence, BZM could not trigger endoplasmic reticulum stress or caspase-7 activation, and did not induce tumor cell death. Taken together, our results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of BZM and suggest that consumption of green tea products may be contraindicated during cancer therapy with BZM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Therapeutic use of tea derivatives: all that glitters is not gold
- Cesare Mancuso and Eugenio Barone
Blood 2009 114: 2359-2360.
[Full Text]
[PDF]
-
From orbital hybridization to chemotherapeutics neutralization
- Nilanjan Ghosh and Ashkan Emadi
Blood 2009 113: 6262.
[Full Text]
[PDF]
-
Bortezomib and EGCG: no green tea for you?
- Jatin J. Shah, Deborah J. Kuhn, and Robert Z. Orlowski
Blood 2009 113: 5695-5696.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
Q. Wang, J. Li, J. Gu, B. Huang, Y. Zhao, D. Zheng, Y. Ding, and L. Zeng
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells
Acta Biochim Biophys Sin,
November 10, 2009;
(2009)
gmp094v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mancuso and E. Barone
Therapeutic use of tea derivatives: all that glitters is not gold
Blood,
September 10, 2009;
114(11):
2359 - 2360.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Shord, K. Shah, and A. Lukose
Drug--Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals
Integr Cancer Ther,
September 1, 2009;
8(3):
208 - 227.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. Ghosh and A. Emadi
From orbital hybridization to chemotherapeutics neutralization
Blood,
June 11, 2009;
113(24):
6262 - 6262.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Shah, D. J. Kuhn, and R. Z. Orlowski
Bortezomib and EGCG: no green tea for you?
Blood,
June 4, 2009;
113(23):
5695 - 5696.
[Full Text]
[PDF]
|
|
|
|
|
